Unlike everyday supplements stocked in every health store, CJC-1295 moves through a specialist research supply market that Milis residents navigate through international suppliers. The practical takeaway for Milis researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the quality verification approach is universal across all locations. Separating quality CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram confirming ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Milis researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Milis comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor make batch-matched COAs available before purchase? Suppliers that publish proactively are demonstrating research-grade standards. The HPLC purity trace is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be at or above 98%. Red flags in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. Store lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to Milis
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and limited human studies. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger dangerous immune responses at very low concentrations, and no discount compensates for this missing data. Protocol documentation — documenting product details, dates, and administration precisely — is a sound practice for any CJC-1295 protocol that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
